Raymond James & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $3.01M | Sell |
10,942
-5,315
| -33% | -$1.46M | ﹤0.01% | 1969 |
|
|
2024
Q2 | $3.95M | Buy |
16,257
+1,089
| +7% | +$265K | ﹤0.01% | 1754 |
|
|
2024
Q1 | $2.27M | Buy |
15,168
+882
| +6% | +$132K | ﹤0.01% | 2079 |
|
|
2023
Q4 | $2.73M | Buy |
14,286
+1,875
| +15% | +$359K | ﹤0.01% | 1898 |
|
|
2023
Q3 | $2.2M | Buy |
12,411
+598
| +5% | +$106K | ﹤0.01% | 1960 |
|
|
2023
Q2 | $2.24M | Buy |
11,813
+1,230
| +12% | +$234K | ﹤0.01% | 1976 |
|
|
2023
Q1 | $2.12M | Sell |
10,583
-534
| -5% | -$107K | ﹤0.01% | 1992 |
|
|
2022
Q4 | $2.64M | Buy |
11,117
+500
| +5% | +$119K | ﹤0.01% | 1819 |
|
|
2022
Q3 | $2.13M | Sell |
10,617
-5,524
| -34% | -$1.11M | ﹤0.01% | 1922 |
|
|
2022
Q2 | $2.35M | Sell |
16,141
-16,919
| -51% | -$2.47M | ﹤0.01% | 1887 |
|
|
2022
Q1 | $5.4M | Sell |
33,060
-10,443
| -24% | -$1.71M | ﹤0.01% | 1458 |
|
|
2021
Q4 | $7.38M | Buy |
43,503
+3,802
| +10% | +$645K | 0.01% | 1286 |
|
|
2021
Q3 | $7.5M | Sell |
39,701
-87
| -0.2% | -$16.4K | 0.01% | 1234 |
|
|
2021
Q2 | $6.75M | Buy |
39,788
+3,157
| +9% | +$535K | 0.01% | 1301 |
|
|
2021
Q1 | $5.17M | Buy |
36,631
+2,727
| +8% | +$385K | 0.01% | 1409 |
|
|
2020
Q4 | $4.41M | Buy |
33,904
+2,261
| +7% | +$294K | ﹤0.01% | 1408 |
|
|
2020
Q3 | $4.61M | Buy |
31,643
+1,018
| +3% | +$148K | 0.01% | 1272 |
|
|
2020
Q2 | $4.54M | Buy |
30,625
+4,121
| +16% | +$610K | 0.01% | 1245 |
|
|
2020
Q1 | $2.89M | Buy |
26,504
+24,540
| +1,249% | +$2.67M | ﹤0.01% | 1360 |
|
|
2019
Q4 | $226K | Buy |
+1,964
| New | +$226K | ﹤0.01% | 3245 |
|
|
2016
Q3 | – | Sell |
-4,008
| Closed | -$222K | – | 3072 |
|
|
2016
Q2 | $222K | Buy |
+4,008
| New | +$222K | ﹤0.01% | 2582 |
|